MAYNE Pharma has announced that it has received further correspondence from Cosette alleging breaches of misleading or deceptive conduct relating to the FDA concerns around its Nextstellis contraceptive pill (PD 19 Jun).
This is the third such notice, with Cosette stating that it intends to terminate its plan to take over Mayne if the circumstances giving rise to the alleged breach continue to exist for five business days.
Mayne maintains there is no new information and the deal can go ahead as planned.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Aug 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Aug 25
